JP2022530599A5 - - Google Patents
Info
- Publication number
- JP2022530599A5 JP2022530599A5 JP2021545411A JP2021545411A JP2022530599A5 JP 2022530599 A5 JP2022530599 A5 JP 2022530599A5 JP 2021545411 A JP2021545411 A JP 2021545411A JP 2021545411 A JP2021545411 A JP 2021545411A JP 2022530599 A5 JP2022530599 A5 JP 2022530599A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022179201A JP2023011902A (ja) | 2020-05-26 | 2022-11-09 | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029757P | 2020-05-26 | 2020-05-26 | |
| US63/029,757 | 2020-05-26 | ||
| US202063069942P | 2020-08-25 | 2020-08-25 | |
| US63/069,942 | 2020-08-25 | ||
| US202163160074P | 2021-03-12 | 2021-03-12 | |
| US63/160,074 | 2021-03-12 | ||
| US202163174474P | 2021-04-13 | 2021-04-13 | |
| US63/174,474 | 2021-04-13 | ||
| US202163181434P | 2021-04-29 | 2021-04-29 | |
| US63/181,434 | 2021-04-29 | ||
| US202163185881P | 2021-05-07 | 2021-05-07 | |
| US63/185,881 | 2021-05-07 | ||
| PCT/US2021/034000 WO2021242728A1 (en) | 2020-05-26 | 2021-05-25 | Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022179201A Division JP2023011902A (ja) | 2020-05-26 | 2022-11-09 | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530599A JP2022530599A (ja) | 2022-06-30 |
| JP2022530599A5 true JP2022530599A5 (https=) | 2022-11-29 |
| JP7240512B2 JP7240512B2 (ja) | 2023-03-15 |
Family
ID=76859703
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545411A Active JP7240512B2 (ja) | 2020-05-26 | 2021-05-25 | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 |
| JP2022179201A Pending JP2023011902A (ja) | 2020-05-26 | 2022-11-09 | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022179201A Pending JP2023011902A (ja) | 2020-05-26 | 2022-11-09 | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210403567A1 (https=) |
| EP (1) | EP4157464A1 (https=) |
| JP (2) | JP7240512B2 (https=) |
| KR (1) | KR20230015954A (https=) |
| CN (1) | CN115666724A (https=) |
| AU (1) | AU2021280245A1 (https=) |
| CA (1) | CA3168738A1 (https=) |
| IL (1) | IL298273A (https=) |
| MX (1) | MX2022014734A (https=) |
| TW (1) | TWI899236B (https=) |
| WO (1) | WO2021242728A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318426A (en) * | 2022-08-02 | 2025-03-01 | Regeneron Pharma | Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28 in combination with anti-PD-1 antibodies |
| TWI887800B (zh) * | 2022-10-12 | 2025-06-21 | 美商默沙東有限責任公司 | 經由皮下投予抗pd1抗體以治療癌症之組合物及方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2689760C2 (ru) | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| US10241115B2 (en) | 2013-12-10 | 2019-03-26 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| KR102410090B1 (ko) * | 2014-02-21 | 2022-06-16 | 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 | 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제 |
| KR102476226B1 (ko) | 2014-08-05 | 2022-12-12 | 아폴로믹스 인코포레이티드 | 항-pd-l1 항체 |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| ES2791950T3 (es) | 2015-02-03 | 2020-11-06 | Ventana Med Syst Inc | Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1) |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US20180155429A1 (en) | 2015-05-28 | 2018-06-07 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| SG11201808626WA (en) | 2016-04-07 | 2018-10-30 | Chemocentryx Inc | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JP7348072B2 (ja) * | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | 三重併用抗体療法 |
| WO2020018789A1 (en) * | 2018-07-18 | 2020-01-23 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
-
2021
- 2021-05-25 MX MX2022014734A patent/MX2022014734A/es unknown
- 2021-05-25 JP JP2021545411A patent/JP7240512B2/ja active Active
- 2021-05-25 KR KR1020227044723A patent/KR20230015954A/ko active Pending
- 2021-05-25 TW TW110118832A patent/TWI899236B/zh active
- 2021-05-25 US US17/329,545 patent/US20210403567A1/en active Pending
- 2021-05-25 CA CA3168738A patent/CA3168738A1/en active Pending
- 2021-05-25 AU AU2021280245A patent/AU2021280245A1/en active Pending
- 2021-05-25 IL IL298273A patent/IL298273A/en unknown
- 2021-05-25 EP EP21740277.5A patent/EP4157464A1/en active Pending
- 2021-05-25 CN CN202180038141.0A patent/CN115666724A/zh active Pending
- 2021-05-25 WO PCT/US2021/034000 patent/WO2021242728A1/en not_active Ceased
-
2022
- 2022-11-09 JP JP2022179201A patent/JP2023011902A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012236479B2 (en) | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments | |
| JP2020508317A5 (https=) | ||
| IL317348A (en) | Stable formulations of PROGRAMMED DEATH RECEPTOR 1 (PD–1) antibodies and methods of using them | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| KR102104296B1 (ko) | 종양성 질병들에 대한 치료 | |
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| JP2018515493A5 (https=) | ||
| CN108079292A (zh) | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 | |
| WO2017205216A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| JP2022530599A5 (https=) | ||
| TW201922273A (zh) | 用於治療肝癌之組合物及方法 | |
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN109806393B (zh) | 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途 | |
| JP2022513029A5 (https=) | ||
| JP2023500480A5 (https=) | ||
| CN109793892B (zh) | 一种抗pd-1抗体在制备治疗食管癌的药物中的用途 | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| WO2026022216A1 (en) | Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases | |
| WO2026021442A1 (zh) | 抗体药物偶联物在制备治疗肺癌的药物中的用途 | |
| JP2024536201A5 (https=) |